News - Cardio-vascular, Diabetes


Current filters:


Popular Filters

1 to 25 of 32 results

FDA review of CV risks for diabetics taking olmesartan not conclusive

FDA review of CV risks for diabetics taking olmesartan not conclusive


The US Food and Drug Administration has completed its safety review and has found no clear evidence of…

BenicarCardio-vascularDaiichi SankyoDiabetesolmesartanPharmaceuticalRegulationUSA

Ligand licenses five programs to Viking Therapeutics


US drugmaker Ligand Pharmaceuticals has out-licensed rights to five programs to Viking Therapeutics,…

Cardio-vascularDiabetesFinancialLicensingLigand PharmaceuticalsMetabolicsPharmaceuticalViking Therapeutics

Takeda files for diabetes drug trelagliptin succinate approval in Japan

Takeda files for diabetes drug trelagliptin succinate approval in Japan


Takeda Pharmaceutical, Japan’s largest drugmaker, has submitted a New Drug Application to the Japanese…

Asia-PacificBlopressCardio-vascularDiabetesJapanPharmaceuticalRegulationResearchTakeda Pharmaceuticalstrelagliptin

Case study draws attention to innovator brand preferences in Kenya


Some of the stronger performing brands in Kenya’s pharmaceutical market have been highlighted in a…

Antibiotics and Infectious diseasesCardio-vascularDiabetesGlaxoSmithKlineMarkets & MarketingPharmaceuticalRest of the World

Sanofi strengthens its presence in Algeria with €70 million investment

Sanofi strengthens its presence in Algeria with €70 million investment


French drug major Sanofi revealed today that construction has begun on its new Sidi Abdellah industrial…

Cardio-vascularDiabetesFinancialPharmaceuticalProductionRest of the WorldSanofi

Further highlights from European Society of Cardiology meeting


The ongoing European Society of Cardiology meeting in Amsterdam, Netherlands, continues to produce both…

ActelionalogliptinAmgenBiotechnologyCardio-vascularCytokineticsDiabetesomecamtiv mecarbilOpsumitPharmaceuticalResearchRespiratory and PulmonaryTakeda Pharmaceuticals

Akrikhin expands deal with Merck & Co


Leading Russian drugmaker Akrikhin says it has expanded its partnership with US pharma giant Merck &…

Akrikhin PharmaceuticalsCardio-vascularDiabetesEuropeEzetrolJanumetJanuviaMarkets & MarketingMerck & CoNoxafilPharmaceuticalProductionRespiratory and PulmonarySingulair

Isis Pharma stock leaps, as investigational drug shown to reduce triglycerides in Ph II study


US biotech firm Isis Pharmaceuticals (Nasdaq: ISIS) saw its shares leap as much as 22% to $26.89 on Monday,…

BiotechnologyCardio-vascularDiabetesIsis PharmaceuticalsISIS-APOCIIIrxResearch

Sanofi plans acceleration of expansion into Ukraine this year


French drug major Sanofi (Euronext: SAN) is considering expanding its presence in Ukraine this year,…

Cardio-vascularDiabetesEuropeMarkets & MarketingPharmaceuticalProductionSanofi

Bristol-Myers gets added indication from US FDA for Sustiva; signs second deal with Ambrx


US pharma major Bristol-Myers Squibb (NYSE: BMY) says that the US Food and Drug Administration has approved…

AmbrxAnti-viralsBiotechnologyBristol-Myers SquibbCardio-vascularDiabetesLicensingNorth AmericaPharmaceuticalRegulationSustiva

Merck & Co opens new $120 million manufacturing plant in China


US Pharma giant Merck & Co (NYSE: MRK) has opened its new pharmaceutical manufacturing facility in Hangzhou,…

Asia-PacificCardio-vascularDiabetesFinancialMerck & CoPharmaceuticalProductionRespiratory and Pulmonary

Gilead's Ranexa reduces angina frequency in patients with type 2 diabetes


US biotech firm Gilead Sciences (Nasdaq: GILD) has announced data from the Phase IV TERISA (Type 2 Diabetes…

BiotechnologyCardio-vascularDiabetesGilead SciencesPharmaceuticalRanexaResearch

Japanese approvals for Novo's Ryzodeg, UCB/Otsuka's Neupro and B-MS/Pfizer's Eliquis


Danish insulin giant Novo Nordisk (NOVN: NV) revealed on December 15 that the Japanese Ministry of Health,…

Asia-PacificBristol-Myers SquibbCardio-vascularDiabetesEliquisNeuproNeurologicalNovo NordiskOtsukaPfizerPharmaceuticalRegulationRyzodegUCB

Germany invalidates Seroquel patent; Merck drops combo diabetes drug development


Anglo-Swedish drug major AstraZeneca (LSE: AZN) said last evening that the Federal Patent Court in Germany…

AstraZenecaatorvastatinCardio-vascularDiabetesJanuviaMerck & CoMK-0431ENeurologicalPatentsPharmaceuticalResearchSeroquel XR

Market for regenerative medicine set to reach $1.4 billion in 2012; report


The overall global market for translational regenerative medicine will reach a value of $1.4 billion…

BiotechnologyCardio-vascularDiabetesGlobalMarkets & MarketingOncologyPharmaceutical

EMA unit backs approval of Jentadueto; Agency updates on Pradaxa


Independent German drug major Boehringer Ingelheim and US partner Eli Lilly (NYSE: LLY) have received…

Boehringer IngelheimCardio-vascularDiabetesEli LillyEuropeJentaduetoPharmaceuticalPradaxaRegulation

Scripps researchers create compounds with potential to treat range of disorders, inc obesity and diabetes


Scientists from the Florida, USA, campus of The Scripps Research Institute have synthesized a pair of…


1 to 25 of 32 results

Company Spotlight

Eleven Biotherapeutics

Eleven Biotherapeutics

Back to top